A Phase 3 interventional study of 5-Fluorouracil and Cyclophosphamide in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 106 sites in 26 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-23.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.
Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 30th largest by enrollment of the 366 interventional ones that give a count, is one of 17 that started in 2009, is one of 60 in phase 3, and was the 142nd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
SWOG Cancer Research Network · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
Institut Curie · Sites in France
Ages 18+
By country, each count listing its studies:
Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab is the comparator here: what the treatment under test is measured against. Read study by study →
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 270 · Phase 3 61 · Phase 4 7
First in 1998; this study’s year is marked. 17 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 596 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 61 across the 366 interventional studies. Of the 235 that completed or were terminated, 128 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 374 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 28th largest by enrollment of the 170 interventional ones that give a count, is one of 18 that started in 2009, is one of 61 in phase 3, and was the 57th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
22 of the studies testing trastuzumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06035679Youzhi ZhuPyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer | 2026-11-30 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT04886531Ruth O'ReganTrial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | 2026-12-22 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07635342Hebei Medical University Fourth HospitalPyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 374 studies testing trastuzumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
In this open-label multicenter trial, participants with operable or locally advanced breast cancer will be randomized to pre-operative treatment with 8 cycles of chemotherapy (4 cycles of docetaxel followed by 4 cycles of 5-fluorouracil, epirubicin, and cyclophosphamide) concurrent with either SC Herceptin or IV Herceptin. After surgery, participants will receive a further 10 cycles of SC or IV Herceptin as per randomization to complete 1 year of treatment. All cycles will be 21 days in length. After the end of study treatment, participants will be followed for safety and efficacy for up to 5 years or until disease recurrence, whichever is earlier.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Herceptin via IV infusion for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin IV will be given on Day 1 of each 21-day cycle, as 8 milligrams per kilogram (mg/kg) for a loading dose during Cycle 1 and as 6 mg/kg during subsequent cycles.
Drug: 5-Fluorouracil · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Epirubicin · Drug: Herceptin IV [trastuzumab]
Participants will receive Herceptin via SC injection for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin SC will be given on Day 1 of each 21-day cycle, as a 600-milligram (mg) fixed dose.
Drug: 5-Fluorouracil · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Epirubicin · Drug: Herceptin SC [trastuzumab]
Participants will receive 5-fluorouracil, 500 milligrams per meter-squared (mg/m\^2) via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
Participants will receive cyclophosphamide, 500 mg/m\^2 via IV bolus, on Day 1 of every 21-day cycle during Cycles 5 to 8.
Participants will receive docetaxel, 75 mg/m\^2 via IV infusion on Day 1 of every 21-day cycle during Cycles 1 to 4.
Participants will receive epirubicin, 75 mg/m\^2 via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
Herceptin will be administered as 8 mg/kg (loading dose during Cycle 1) and 6 mg/kg (subsequent cycles) via IV infusion on Day 1 of each 21-day cycle for a total of 18 cycles.
Herceptin will be administered as fixed dose 600 mg SC on Day 1 of each 21-day cycle for a total of 18 cycles.
Observed Serum Trough Concentration (Ctrough) of Trastuzumab Prior to Surgery
Pre-dose samples were obtained prior to surgery (Cycle 8). The observed Ctrough was recorded, averaged among all participants, and expressed in micrograms per milliliter (μg/mL).
Time frame: Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Percentage of Participants With Pathological Complete Response (pCR)
Participants were evaluated following eight cycles of treatment and after surgery to assess for pCR, defined as absence of neoplastic invasive cells in the breast according to pathologist examination. The percentage of participants with pCR was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method.
Time frame: After surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months from Baseline)
Observed Ctrough of Trastuzumab After Surgery
Pre-dose samples were obtained after surgery (Cycle 13). The observed Ctrough was recorded, averaged among all participants, and expressed in μg/mL.
Time frame: Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Predicted Ctrough of Trastuzumab Prior to Surgery
Predicted Ctrough at pre-dose prior to surgery (Cycle 8) was determined on the basis of a population PK model from Study BP22023 (NCT00800436). The mean predicted Ctrough was expressed in μg/mL.
Time frame: Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Predicted Ctrough of Trastuzumab After Surgery
Predicted Ctrough at pre-dose after surgery (Cycle 13) was determined on the basis of a population PK model from Study BP22023 (NCT00800436). The mean predicted Ctrough was expressed in μg/mL.
Time frame: Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Number of Participants With Ctrough of Trastuzumab >20 μg/mL Prior to Surgery
Pre-dose samples were obtained prior to surgery (Cycle 8). The number of participants who had an observed Ctrough \>20 μg/mL was reported.
Time frame: Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Number of Participants With Ctrough of Trastuzumab >20 μg/mL After Surgery
Pre-dose samples were obtained after surgery (Cycle 13). The number of participants who had an observed Ctrough \>20 μg/mL was reported.
Time frame: Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Maximum Serum Concentration (Cmax) of Trastuzumab Prior to Surgery
PK samples were obtained prior to surgery (Cycle 7). The Cmax during Cycle 7 was recorded, averaged among all participants, and expressed in μg/mL.
Time frame: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Time of Maximum Serum Concentration (Tmax) of Trastuzumab Prior to Surgery
PK samples were obtained prior to surgery (Cycle 7). The Tmax during Cycle 7 was recorded, averaged among all participants, and expressed in days.
Time frame: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Area Under the Concentration-Time Curve From 0 to 21 Days (AUC21d) of Trastuzumab Prior to Surgery
PK samples were obtained prior to surgery (Cycle 7). Values were extrapolated beyond Day 15 to produce the area over the full 21-day cycle. The AUC21d value at Cycle 7 was calculated from trastuzumab concentration-time profiles using standard non-compartmental PK methods, averaged among all participants, and expressed in days multiplied by micrograms per milliliters (d\*μg/mL).
Time frame: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Cmax of Trastuzumab After Surgery
PK samples were obtained after surgery (Cycle 12). The Cmax during Cycle 12 was recorded, averaged among all participants, and expressed in μg/mL.
Time frame: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Tmax of Trastuzumab After Surgery
PK samples were obtained after surgery (Cycle 12). The Tmax during Cycle 12 was recorded, averaged among all participants, and expressed in days.
Time frame: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
AUC21d of Trastuzumab After Surgery
PK samples were obtained after surgery (Cycle 12). Values were extrapolated beyond Day 15 to produce the area over the full 21-day cycle. The AUC21d value at Cycle 12 was calculated from trastuzumab concentration-time profiles using standard non-compartmental PK methods, averaged among all participants, and expressed in d\*μg/mL.
Time frame: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Percentage of Participants With Total Pathological Complete Response (tpCR)
Participants were evaluated following eight cycles of treatment and after surgery to assess for tpCR, defined as absence of neoplastic invasive cells in the breast and axillary lymph nodes according to pathologist examination. The percentage of participants with tpCR was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method.
Time frame: After surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months from Baseline)
Percentage of Participants With Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0, Among Those With Measurable Disease at Baseline
Tumor response was assessed using RECIST version 1.0. CR was defined as disappearance of all target lesions and short-axis reduction of any pathological lymph nodes to less than (\<) 10 millimeters (mm) with no prior assessment of progressive disease (PD). PR was defined as greater than or equal to (≥) 30% decrease from Baseline in sum diameter (SD) of target lesions with no prior assessment of PD. PD was defined as ≥20% relative increase and ≥5 mm of absolute increase in the SD of target lesions, taking as reference the smallest SD recorded since treatment started; or appearance of 1 or more new lesions. The percentage of participants with overall response of CR or PR at the end of neoadjuvant treatment was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method.
Time frame: Tumor assessments at Baseline; on Day 1 of Cycles 3, 5, 7 (cycle length of 21 days); and at time of surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months overall)
Time to Response According to RECIST Version 1.0, Among Those With Measurable Disease at Baseline
Tumor response was assessed using RECIST version 1.0. CR was defined as disappearance of all target lesions and short-axis reduction of any pathological lymph nodes to \<10 mm with no prior assessment of PD. PR was defined as ≥30% decrease from Baseline in SD of target lesions with no prior assessment of PD. PD was defined as ≥20% relative increase and ≥5 mm of absolute increase in the SD of target lesions, taking as reference the smallest SD recorded since treatment started; or appearance of 1 or more new lesions. Time to response was defined as the time from first dose of study medication to the first assessment of CR or PR, which was the date the response was first documented by objective evidence, among participants with an overall response of CR or PR.
Time frame: Tumor assessments at Baseline; on Day 1 Cycles 3, 5, 7 (cycle length of 21 days); and at time of surgery following eight cycles of chemotherapy (approximately 6 months overall)
Percentage of Participants Who Experienced a Protocol-Defined Event
Protocol-defined events included disease recurrence/progression (local, regional, distant, contralateral) or death from any cause. Imaging was performed at specified visits for up to 5 years after last dose. Thereafter, participants were followed for survival only. The percentage of participants who experienced a protocol-defined event at any time during the study was reported.
Time frame: Screening; Day 1 of Cycle 18 (cycle length of 21 days); and Months 6, 12, 24, 36, 48, 60 from last dose of Cycle 18; then every 6 months until withdrawal for any reason (up to approximately 87 months overall)
Event-Free Survival (EFS)
Protocol-defined events included disease recurrence or progression (local, regional, distant, contralateral) or death from any cause. Imaging was performed at specified visits for up to 5 years after last dose. Thereafter, participants were followed for survival only. EFS was estimated by Kaplan-Meier analysis and defined as the time from randomization to the first protocol-defined event.
Time frame: Screening; Day 1 of Cycle 18 (cycle length of 21 days); and Months 6, 12, 24, 36, 48, 60 from last dose of Cycle 18; then every 6 months until withdrawal for any reason (up to approximately 87 months overall)
Percentage of Participants Who Died
The percentage of participants who died at any time during the study was reported.
Time frame: Continuously during treatment (up to 12 months); at Months 1, 3, 6 from last dose of Cycle 18 (cycle length of 21 days); then every 6 months until withdrawal for any reason (up to approximately 87 months overall)
Overall Survival (OS)
OS was estimated by Kaplan-Meier analysis and defined as the time from randomization to death from any cause.
Time frame: Continuously during treatment (up to 12 months); at Months 1, 3, 6 from last dose of Cycle 18 (cycle length of 21 days); then every 6 months until withdrawal for any reason (up to approximately 87 months overall)
Number of Participants With Anti-Drug Antibodies (ADAs) Against Trastuzumab
Participants provided PK samples for evaluation of anti-trastuzumab antibodies. The number of participants with "Treatment-induced ADAs" and "Treatment-enhanced ADA" against trastuzumab at any time during or after treatment was reported. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result (four-fold increase of titer).
Time frame: Baseline; pre-dose (0 hours) on Day 1 of Cycles 2, 5, 13, 18 (cycle length of 21 days); and Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 from last dose of Cycle 18
Number of Participants With ADAs Against Recombinant Human Hyaluronidase (rHuPH20)
Participants in the Herceptin SC arm provided PK samples for evaluation of anti-rHuPH20 antibodies. The number of participants with "Treatment-induced ADAs" and "Treatment-enhanced ADA" against rHuPH20 (an excipient unique to the SC formulation) at any time during or after treatment was reported. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result (four-fold increase of titer).
Time frame: Baseline; pre-dose (0 hours) on Day 1 of Cycles 2, 5, 13, 18 (cycle length of 21 days); and Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 from last dose of Cycle 18
| Milestone | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Started | 299 | 297 |
| Received neoadjuvant treatment | 298 | 297 |
| Underwent surgery | 277 | 273 |
| Entered adjuvant treatment | 277 | 274 |
| Completed | 257 | 255 |
| Not completed | 42 | 42 |
| Withdrew: Adverse event or intercurrent illness | 6 | 15 |
| Withdrew: Death | 1 | 3 |
| Withdrew: Insufficient therapeutic response | 3 | 0 |
| Withdrew: Violation of selection criteria | 2 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Participant refusal/withdrawal | 4 | 5 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Progression of disease | 12 | 11 |
| Withdrew: Recurrence of disease | 10 | 5 |
| Withdrew: Other | 1 | 1 |
| Milestone | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Started | 265 | 268 |
| Completed | 165 | 161 |
| Not completed | 100 | 107 |
| Withdrew: Adverse event or intercurrent illness | 3 | 4 |
| Withdrew: Death | 4 | 1 |
| Withdrew: Refused treatment | 10 | 11 |
| Withdrew: Failure to return | 16 | 16 |
| Withdrew: Recurrence of disease | 63 | 72 |
| Withdrew: Other | 4 | 3 |
| Milestone | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Started | 118 | 123 |
| Completed | 40 | 45 |
| Not completed | 78 | 78 |
| Withdrew: Death | 44 | 42 |
| Withdrew: Lost to follow-up | 30 | 28 |
| Withdrew: Withdrawal by subject | 4 | 8 |
Pre-dose samples were obtained prior to surgery (Cycle 8). The observed Ctrough was recorded, averaged among all participants, and expressed in micrograms per milliliter (μg/mL).
| μg/mL | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Observed Serum Trough Concentration (Ctrough) of Trastuzumab Prior to Surgery | 57.8 ± 30.3 | 78.7 ± 43.9 |
Participants were evaluated following eight cycles of treatment and after surgery to assess for pCR, defined as absence of neoplastic invasive cells in the breast according to pathologist examination. The percentage of participants with pCR was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method.
| percentage of participants | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Percentage of Participants With Pathological Complete Response (pCR) | 40.7 (34.7 to 46.9) | 45.4 (39.2 to 51.7) |
Pre-dose samples were obtained after surgery (Cycle 13). The observed Ctrough was recorded, averaged among all participants, and expressed in μg/mL.
| μg/mL | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Observed Ctrough of Trastuzumab After Surgery | 62.1 ± 37.1 | 90.4 ± 41.9 |
Predicted Ctrough at pre-dose prior to surgery (Cycle 8) was determined on the basis of a population PK model from Study BP22023 (NCT00800436). The mean predicted Ctrough was expressed in μg/mL.
| μg/mL | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Predicted Ctrough of Trastuzumab Prior to Surgery | 51.4 ± 19.4 | 80.3 ± 33.2 |
Predicted Ctrough at pre-dose after surgery (Cycle 13) was determined on the basis of a population PK model from Study BP22023 (NCT00800436). The mean predicted Ctrough was expressed in μg/mL.
| μg/mL | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Predicted Ctrough of Trastuzumab After Surgery | 51.7 ± 20.0 | 80.6 ± 33.4 |
Pre-dose samples were obtained prior to surgery (Cycle 8). The number of participants who had an observed Ctrough \>20 μg/mL was reported.
| participants | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Number of Participants With Ctrough of Trastuzumab >20 μg/mL Prior to Surgery | 232 | 227 |
Pre-dose samples were obtained after surgery (Cycle 13). The number of participants who had an observed Ctrough \>20 μg/mL was reported.
| participants | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Number of Participants With Ctrough of Trastuzumab >20 μg/mL After Surgery | 216 | 227 |
PK samples were obtained prior to surgery (Cycle 7). The Cmax during Cycle 7 was recorded, averaged among all participants, and expressed in μg/mL.
| μg/mL | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Maximum Serum Concentration (Cmax) of Trastuzumab Prior to Surgery | 221 ± 118 | 149 ± 64.8 |
PK samples were obtained prior to surgery (Cycle 7). The Tmax during Cycle 7 was recorded, averaged among all participants, and expressed in days.
| days | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Time of Maximum Serum Concentration (Tmax) of Trastuzumab Prior to Surgery | 0.05 ± 0.04 | 4.12 ± 2.91 |
PK samples were obtained prior to surgery (Cycle 7). Values were extrapolated beyond Day 15 to produce the area over the full 21-day cycle. The AUC21d value at Cycle 7 was calculated from trastuzumab concentration-time profiles using standard non-compartmental PK methods, averaged among all participants, and expressed in days multiplied by micrograms per milliliters (d\*μg/mL).
| d*μg/mL | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Area Under the Concentration-Time Curve From 0 to 21 Days (AUC21d) of Trastuzumab Prior to Surgery | 2056 ± 598 | 2268 ± 875 |
PK samples were obtained after surgery (Cycle 12). The Cmax during Cycle 12 was recorded, averaged among all participants, and expressed in μg/mL.
| μg/mL | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Cmax of Trastuzumab After Surgery | 230 ± 118 | 166 ± 58.8 |
PK samples were obtained after surgery (Cycle 12). The Tmax during Cycle 12 was recorded, averaged among all participants, and expressed in days.
| days | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Tmax of Trastuzumab After Surgery | 0.06 ± 0.13 | 4.08 ± 2.87 |
PK samples were obtained after surgery (Cycle 12). Values were extrapolated beyond Day 15 to produce the area over the full 21-day cycle. The AUC21d value at Cycle 12 was calculated from trastuzumab concentration-time profiles using standard non-compartmental PK methods, averaged among all participants, and expressed in d\*μg/mL.
| d*μg/mL | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| AUC21d of Trastuzumab After Surgery | 2179 ± 725 | 2610 ± 945 |
Participants were evaluated following eight cycles of treatment and after surgery to assess for tpCR, defined as absence of neoplastic invasive cells in the breast and axillary lymph nodes according to pathologist examination. The percentage of participants with tpCR was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method.
| percentage of participants | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Percentage of Participants With Total Pathological Complete Response (tpCR) | 34.2 (28.5 to 40.3) | 39.2 (33.3 to 45.5) |
Tumor response was assessed using RECIST version 1.0. CR was defined as disappearance of all target lesions and short-axis reduction of any pathological lymph nodes to less than (\<) 10 millimeters (mm) with no prior assessment of progressive disease (PD). PR was defined as greater than or equal to (≥) 30% decrease from Baseline in sum diameter (SD) of target lesions with no prior assessment of PD. PD was defined as ≥20% relative increase and ≥5 mm of absolute increase in the SD of target lesions, taking as reference the smallest SD recorded since treatment started; or appearance of 1 or more new lesions. The percentage of participants with overall response of CR or PR at the end of neoadjuvant treatment was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method.
| percentage of participants | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Percentage of Participants With Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0, Among Those With Measurable Disease at Baseline | 88.8 (84.4 to 92.4) | 87.2 (82.5 to 91.0) |
Tumor response was assessed using RECIST version 1.0. CR was defined as disappearance of all target lesions and short-axis reduction of any pathological lymph nodes to \<10 mm with no prior assessment of PD. PR was defined as ≥30% decrease from Baseline in SD of target lesions with no prior assessment of PD. PD was defined as ≥20% relative increase and ≥5 mm of absolute increase in the SD of target lesions, taking as reference the smallest SD recorded since treatment started; or appearance of 1 or more new lesions. Time to response was defined as the time from first dose of study medication to the first assessment of CR or PR, which was the date the response was first documented by objective evidence, among participants with an overall response of CR or PR.
| weeks | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Time to Response According to RECIST Version 1.0, Among Those With Measurable Disease at Baseline | 6.14 (3 to 25) | 6.14 (3 to 28) |
Protocol-defined events included disease recurrence/progression (local, regional, distant, contralateral) or death from any cause. Imaging was performed at specified visits for up to 5 years after last dose. Thereafter, participants were followed for survival only. The percentage of participants who experienced a protocol-defined event at any time during the study was reported.
| percentage of participants | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Percentage of Participants Who Experienced a Protocol-Defined Event | 33.3 | 32.7 |
Protocol-defined events included disease recurrence or progression (local, regional, distant, contralateral) or death from any cause. Imaging was performed at specified visits for up to 5 years after last dose. Thereafter, participants were followed for survival only. EFS was estimated by Kaplan-Meier analysis and defined as the time from randomization to the first protocol-defined event.
| months | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Event-Free Survival (EFS) | NA (1 to 82) | NA (1 to 76) |
The percentage of participants who died at any time during the study was reported.
| percentage of participants | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Percentage of Participants Who Died | 14.5 | 13.6 |
OS was estimated by Kaplan-Meier analysis and defined as the time from randomization to death from any cause.
| months | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Overall Survival (OS) | NA (2 to 82) | NA (3 to 79) |
Participants provided PK samples for evaluation of anti-trastuzumab antibodies. The number of participants with "Treatment-induced ADAs" and "Treatment-enhanced ADA" against trastuzumab at any time during or after treatment was reported. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result (four-fold increase of titer).
| participants | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Treatment-induced ADAs | 28 | 46 |
| Treatment-enhanced ADA | 2 | 1 |
Participants in the Herceptin SC arm provided PK samples for evaluation of anti-rHuPH20 antibodies. The number of participants with "Treatment-induced ADAs" and "Treatment-enhanced ADA" against rHuPH20 (an excipient unique to the SC formulation) at any time during or after treatment was reported. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result (four-fold increase of titer).
| participants | Herceptin SC + Chemotherapy |
|---|---|
| Treatment-induced ADA | 49 |
| Treatment-enhanced ADA | 13 |
Collected over Approximately 87 months overall. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Herceptin IV + Chemotherapy | — | 45/298 (15.1%) | 277/298 (93%) |
| Herceptin SC + Chemotherapy | — | 65/297 (21.9%) | 283/297 (95.3%) |
| Event | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 10/298 | 13/297 |
| NeutropeniaBlood and lymphatic system disorders | 9/298 | 7/297 |
| PneumoniaInfections and infestations | 4/298 | 2/297 |
| Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/298 | 2/297 |
| Cardiac failure congestiveCardiac disorders | 0/298 | 2/297 |
| TonsillitisInfections and infestations | 0/298 | 2/297 |
| CellulitisInfections and infestations | 0/298 | 2/297 |
| Lower respiratory tract infectionInfections and infestations | 0/298 | 2/297 |
| Postoperative wound infectionInfections and infestations | 0/298 | 2/297 |
| PyrexiaGeneral disorders | 0/298 | 2/297 |
| Event | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy |
|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 188/298 | 187/297 |
| NauseaGastrointestinal disorders | 147/298 | 145/297 |
| NeutropeniaBlood and lymphatic system disorders | 135/298 | 128/297 |
| DiarrhoeaGastrointestinal disorders | 109/298 | 101/297 |
| FatigueGeneral disorders | 80/298 | 70/297 |
| AstheniaGeneral disorders | 75/298 | 75/297 |
| VomitingGastrointestinal disorders | 69/298 | 69/297 |
| MyalgiaMusculoskeletal and connective tissue disorders | 54/298 | 61/297 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 60/298 | 53/297 |
| Decreased appetiteMetabolism and nutrition disorders | 59/298 | 58/297 |
Intent-to-Treat (ITT) Population: All participants with at least one efficacy assessment after administration of the first treatment cycle.
| Age, Continuous(years) | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy | Total |
|---|---|---|---|
| Mean | 49.5 ± 10.83 | 50.3 ± 11.08 | 49.9 ± 10.95 |
| Sex: Female, Male(Participants) | Herceptin IV + Chemotherapy | Herceptin SC + Chemotherapy | Total |
|---|---|---|---|
| Female | 297 | 294 | 591 |
| Male | 0 | 0 | 0 |
Showing the first 100 of 106 sites across 26 countries. Choose a country and city above to see the rest.
Ran from Oct 2009 to primary completion in Jul 2011, 20 months.
Results were first posted in Jan 2017, 5 years 6 months after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 20 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab